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012.04.00Abstract Aim of work: To investigate osteopontin (OPN) levels in both plasma and synovial ﬂuid
of patients with primary knee osteoarthritis (OA) and their relationship with radiological grade.
Patient and methods: Sixty patients had knee OA and 30 control subjects were included. Anter-
oposterior knee radiographs were taken to determine the disease severity of the affected knee. The
radiographic grading of OA in the knee was performed by using the Kellgren–Lawrence grading.
Osteopontin levels in the plasma and synovial ﬂuid were measured using enzyme-linked immuno-
sorbent assay and compared.
Results: OA patients had higher plasma osteopontin concentrations compared to healthy
controls (p< 0.000). Osteopontin levels in synovial ﬂuid were signiﬁcantly higher with respect to
plasma sample (r= 0.694, p< 0.000). The mean plasma levels of osteopontin in KL grade 4 were
greater than those in KL grade 3, and the difference was statistically signiﬁcant (p< 0.01). The
plasma osteopontin levels signiﬁcantly correlated with the severity of disease (r= 0.870,
p< 0.000). The synovial ﬂuid levels of osteopontin also correlated with disease severity as regarding
the radiological grade (r= 0.817, p< 0.000).
Conclusion: Osteopontin in plasma and synovial ﬂuid is related to progressive joint damage in
knee OA. Osteopontin may serve as a biochemical marker for determining disease severity as regard-
ing radiological grade.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license..com (F.I. Mohammed).
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31. Introduction
Osteoarthritis (OA) is a chronic degenerative joint disease that
is characterized by the progressive destruction of articular car-
tilage with varying degrees of severity within a given joint [1].
OA is a strongly age-related joint disorder that is deﬁned by
focal lesions of the articular cartilage, combined with auction and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
132 F.I. Mohammed et al.hypertrophic reaction (sclerosis) in the subchondral bone and
new bone formation (osteophytes) at the joint margins and
mild, chronic nonspeciﬁc synovial inﬂammation [1].
To identify patients with a high risk for destructive OA and
to monitor drug efﬁcacy, more sensitive techniques than plain
X-rays are needed. Speciﬁc and sensitive biochemical markers
reﬂecting abnormalities of the turnover of bone, cartilage, and
synovial tissues may be useful for the investigation and moni-
toring of OA [2].
Osteopontin is one of the major noncollagenous bone ma-
trix proteins produced by various cell types, including acti-
vated T cells, macrophages, osteoblasts and chondrocytes [3].
Osteopontin may be involved in the molecular pathogenesis
of osteoarthritis, contributing to progressive degeneration of
articular cartilage [4].
Expression of osteopontin mRNA isolated from human
OA cartilage was enhanced as compared with normal cartilage.
Osteopontin was shown to be upregulated in human OA chon-
drocytes [5]. Moreover, osteopontin was found to be expressed
in bone forming cells and hypertrophic chondrocytes of the
embryonic epiphyseal growth plates [6]. Although circulating
and/or synovial ﬂuid levels of several cytokines have been
investigated in patients with knee OA, there have been no de-
tailed studies on plasma and synovial ﬂuid levels of osteopon-
tin in various clinical stages of primary knee OA [7–11].
The purposes of the present study were to investigate the
concentrations of osteopontin in both plasma and synovial
ﬂuid of patients with primary knee osteoarthritis, and to eval-
uate the possible correlations with the radiographic grading of
knee OA.
2. Patients and methods
Sixty OA patients fulﬁlled the American College of Rheuma-
tology (ACR) clinical and radiographic diagnostic criteria
for knee OA [12], and 30 control subjects matched for age
and sex were included in the present study. The patients were
recruited between, December, 2010 and October, 2011 at the
Rheumatology and Rehabilitation Outpatient Clinic, Minia
and Beni Suef University Hospitals.
All patients gave informed consent, and this study was ap-
proved by the local ethics committee.
2.1. Inclusion criteria
Patients with primary knee OA unilateral or bilateral with
chronic knee pain more than three months and radiological
evidence of early OA.
2.2. Exclusion criteria
Patients with secondary OA, e.g. post-traumatic or post-
inﬂammatory, e.g. rheumatoid arthritis (RA), patients with
systemic diseases as renal or hepatic failure or malignancy
and patients with generalized OA or patients with concomitant
knee and hip OA.
2.3. Clinical evaluation
All patients were subjected to: full history, clinical examination
including symptoms and signs of OA, and functional evalua-tion, using Arabic translated and validated version of Western
Ontario and McMaster University (WOMAC) index [13].
2.4. Radiological evaluation
The severity of the disease was determined using weight bear-
ing anteroposterior radiographs of the affected knee. Knee
radiographs were evaluated according to the Kellgren and
Lawrence classiﬁcation [14]: grade 1, doubtful narrowing of
joint space and possible osteophytic lipping; grade 2, deﬁnite
osteophytes and possible narrowing of joint space; grade 3,
moderate multiple osteophytes, deﬁnite narrowing of joints
space, some sclerosis and possible deformity of bone contour;
grade 4, large osteophytes, marked narrowing of joint space,
severe sclerosis and deﬁnite deformity of bone contour. The
grading scale used for analysis was the higher of the two knees.
Radiographic OA was considered present if K–L grade was
more than 2 [15].
2.4.1. Laboratory investigations
Routine and special laboratory tests were done for all patients
and controls. Synovial ﬂuid was aspirated (only from patient)
from the affected knee centrifuged to remove cells and joint
debris and stored immediately at 80 C until the day of mea-
surement, also plasma was stored at 80 C for quantitative
detection of osteopontin by commercial enzyme-linked immu-
nosorbent assay (ELISA). Kit was supplied by R&D Systems
(Berlin Germany).
2.4.2. Principle of osteopontin assay
This assay employs the quantitative sandwich enzyme immu-
noassay technique. A monoclonal antibody speciﬁc for OPN
has been pre-coated onto a microplate. Standards and samples
were pipetted into the wells and any OPN present is bound by
the immobilized antibody. After washing away any unbound
substances, an enzyme-linked polyclonal antibody speciﬁc for
OPN was added to the wells, a substrate solution was added
to the wells and color developed in proportion to the amount
of OPN bound in the initial step. The color development was
stopped and the intensity of the color was measured.
Statistical analysis: Statistical analyses were performed
using SPSS version 17.0 (SPSs, Chicago, IL). Continuous data
were expressed as mean ± standard deviation (SD). The dif-
ferences among OA patients and control were determined by
independent sample t-test. The correlations between OPN
and disease severity parameters were done by Spearman corre-
lation test. Statistical signiﬁcance was set at p< 0.05.3. Results
3.1. Demographic, clinical and laboratory ﬁndings of OA
patients and control group
The study population included 60 patients with knee OA, their
mean age was (54.33 ± 6.94), ranging from 45 to 70 years old.
The mean duration of disease was 6.81 ± 3.19 ranging from 1
to 15 years and 30 healthy volunteers matched for age and sex
served as controls Table 1.
Regarding the clinical ﬁndings detected in OA patients NO
(%) Knee swelling was detected in 43 (71%), Tenderness in 47
Table 1 Demographic data of OA patients and control group.
OA patients (n= 60) Controls (n= 30) p value
Age 54.33 ± 6.94 56.07 ± 5.78 NS
Sex F% 45(75%) 23(78%) NS
Disease duration (6.81 ± 4.19) –
BMI 27.47 ± 8.11 26.18 ± 5.65 NS
Plasma osteopontin 165.33 ± 67.22 56.06 ± 5.77 p< 0.000
BMI = Body Mass Index.
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waisting in 45 (75%), Bony swelling in 12 (20%), Limited mo-
tion in 14 (23%), Baker cyst in 5 (8%), Deformity in 7 (11%),
Instability in 3 (5%) of patients while the mean ± SD of: Inac-
tivity stiffness was (8.67 ± 3.31) minutes, WOMAC mean
(52.69 + 22.78), K/L (2.65 ± 1.01), Synovial osteopontin
(366.83 ± 148.42) knee swelling was the most common symp-
toms while knee tenderness was the most common sign.
OA patients had higher plasma osteopontin concentrations
compared to healthy controls (p< 0.000) Table 1.
Osteopontin levels in synovial ﬂuid were signiﬁcantly higher
with respect to plasma samples (r= 0.694, p< 0.000) Fig. 1.
According to the Kellgren and Lawrence (KL) grading
scale, 7 (12%) patients were KL grade 1, 23 (38%) patients
were KL grade 2, whereas 14 (23%) patients were KL grade
3 and 16 (27%) patients were KL grade 4 osteoarthritis.
3.2. Comparison of the plasma and synovial ﬂuid levels of
osteopontin in relation to radiological KL grading of OA:
Table 2 and Figs. 2 and 3
The plasma osteopontin level was higher in KL grade 4
(252.18 ± 57.93).
These results showed that plasma osteopontin levels in KL
grades 3 and 4 were signiﬁcantly higher than those of KL
grade 2 independently (p< 0.001). The mean plasma levels
of osteopontin in KL grade 4 were greater than those in KL
grade 3, the difference was statistically signiﬁcant (p< 0.01)
Fig. 2.
In addition, the synovial ﬂuid levels of osteopontin from
KL 4 were 192.85 ± 10.74. The data revealed that synovial
ﬂuid osteopontin levels in KL grades 3 and 4 were signiﬁcantlyFigure 1 Plasma and synovial ﬂuid osteopontin levels in patients
and controls.elevated compared with those of KL grade 2 independently
(p< 0.001).
3.3. The correlation between the plasma and synovial ﬂuid levels
of osteopontin with other disease parameters Table 3
The correlation was positive only with age, disease duration,
WOMAC index and K/L grades (total).
The plasma osteopontin levels signiﬁcantly correlated with
disease severity as regarding the radiological grade (r= 0.870,
p< 0.000), and also the synovial ﬂuid levels of osteopontin
signiﬁcantly correlated with disease severity (r= 0.817,
p< 0.000).
There was signiﬁcant correlation between plasma and syno-
vial ﬂuid levels of osteopontin in OA patients (r= 0.694,
p< 0.000) Fig. 4.
4. Discussion
Expression of OPN was shown to be upregulated in OA carti-
lage and synovium. OPN could be involved in synovial cell
attachment to chondrocytes or cartilage matrix, in addition
to its involvement in destruction of cartilage matrix by the pro-
duction of collagenases in articular chondrocytes [4,5,16,17].
Our study was designed to investigate osteopontin (OPN)
levels in both plasma and synovial ﬂuid of patients with pri-
mary knee osteoarthritis (OA) and their relationship with
severity of the disease as regarding the radiological grade.
Our ﬁndings suggest enhanced local and systemic produc-
tion of Osteopontin in primary knee osteoarthritis.
This study showed a marked increase of Osteopontin level
in plasma of patients with primary knee osteoarthritis com-
pared to the control plasma levels (165.33 ± 67.22 vs
56.06 ± 5.77 ng/mL, p< 0.000). This is consistent with the re-
sults of Honsawek et al. [18] who found that, OA patients had
higher plasma osteopontin concentrations compared to
healthy controls (168.8 ± 15.6 vs 67.2 ± 7.7 ng/mL,
p< 0.0001).
In this study osteopontin level in synovial ﬂuid was
signiﬁcantly higher with respect to plasma samples (366.83 ±
148.42 vs 165.33 ± 67.22 ng/mL. r= 0.694, p< 0.000). This
is in agreement with the result of Honsawek et al., [18] who
found that, OPN levels in synovial ﬂuidwere signiﬁcantly higher
with respect to paired plasma samples (272.1 ± 15.0 vs
168.8 ± 15.6 ng/mL, p< 0.001). Also this is in agreement with
the result of Gao et al. [17] who found that, OA patients had
higher synovial ﬂuid OPN concentrations compared to healthy
controls (4519.60_1830.37, 95%CI 3999.42 and 5039.79 vs
1179.70_303.39, 95%CI 1035.53 and 1438.74 pg/ml,
p< 0.001). But our ﬁnding is inconsistent with the results of
Table 2 Plasma and synovial ﬂuid osteopontin levels at KL grading.
OA grades
KL I (n= 7) KL II (n= 23) KL III (n= 14) KL IV (n= 16)
Plasma osteopontin 92.85 ± 8.09 124.73 ± 13.35 181.78 ± 14.4 252.18 ± 57.93.
Synovial osteopontin 192.85 ± 10.74 274.56 ± 36.17 417.14 ± 110.69 531.56 ± 124
KL=Kellgren and Lawrence grades.
Figure 2 Plasma osteopontin levels at different K/L radiological
grades.
Figure 3 Synovial ﬂuid osteopontin levels at different K/L
radiological grades.
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cleaved osteopontin (OPN full-length) in OA knees were not
statistically different from those in controls (p= 0.134). In con-
trast, the levels of N-terminal half of thrombin-cleaved osteo-
pontin (OPN N-half) were signiﬁcantly higher in OA knees
than those in controls (p= 0.042). The % OPN N-half in-
creased signiﬁcantly in OA knees compared to controls
(p= 0.003).Elevated levels of OPN in the SF were possibly caused by
either the release of OPN residing in the local tissues, including
the synovium, articular cartilage, and bone, or the increase in
its production, or both [17,18]. It is suggested that cell adhe-
sion, migration, or inﬂammation could be involved in the re-
lease of OPN [20].
Previous studies have demonstrated the immunohistochem-
ical expression of OPN in the synovial lining cells [10], ﬁbro-
blasts in the synovial tissues [21] and articular chondrocytes
[5,21].
In our study, there was a statistically signiﬁcant difference
in plasma osteopontin levels among patients with OA with dif-
ferent age (p< 0.014), but there was no statistically signiﬁcant
difference in synovial ﬂuid osteopontin levels among patients
with OA (p< 0.396). This is consistent with the result of
Honsawek et al. [18] who found that there was no statistically
signiﬁcant difference in synovial ﬂuid osteopontin levels
among patients with OA with different age (p= 0.5).
In our study, comparing the plasma level of osteopontin in
relation to radiological KL grading of OA, we found that plas-
ma osteopontin levels in KL grades 3 and 4 were signiﬁcantly
higher than those of KL grade 2 (p< 0.001). The mean plas-
ma levels of osteopontin in KL grade 4 were greater than those
in KL grade 3, the difference was statistically signiﬁcant
(p< 0.01). So the plasma osteopontin levels signiﬁcantly cor-
related with the severity of disease (p< 0.000). This is consis-
tent with the result of Honsawek et al. [18] who found that,
plasma osteopontin levels in KL grades 3 and 4 were signiﬁ-
cantly higher than those of KL grade 2 (p< 0.001). Although
the mean plasma levels of osteopontin in KL grade 4 were
greater than those in KL grade 3, the difference was not statis-
tically signiﬁcant (p= 0.835). So the plasma osteopontin levels
signiﬁcantly correlated with the severity of disease (p< 0.001).
In this study, we found positive correlation between plasma
and synovial ﬂuid levels of osteopontin (p= 0.000), this is in
agreement with the result of Honsawek et al. [18], who found
positive correlation between plasma and synovial ﬂuid levels of
osteopontin (p= 0.035).
In our study, analysis and comparing the synovial ﬂuid le-
vel of osteopontin in relation to radiological KL grading of
OA, we found that synovial ﬂuid osteopontin levels in KL
grades 3 and 4 were signiﬁcantly elevated compared with those
of KL grade 2 (p< 0.001). So the synovial ﬂuid levels of oste-
opontin correlated with disease severity (p< 0.000). This is
consistent with the results of Honsawek et al. [18], and Gao
et al. [17], but inconsistent with the results of Hasegawa
et al. [19]. Where, Honsawek et al. [18] revealed that synovial
ﬂuid osteopontin levels in KL grades 3 and 4 were signiﬁcantly
elevated compared with those of KL grade 2 (p< 0.01), so the
synovial ﬂuid levels of osteopontin correlated with disease
severity (p< 0.01).
Table 3 Correlations between osteopontin levels in plasma, and synovial ﬂuid with other disease parameters.
Plasma osteopontin Synovial osteopontin
R p R p
Age 0.314 0.014* 0.114 0.396
Disease duration 0.490 0.006* 0.473 0.008*
WOMAC 0.417 0.005* 0.194 0.213
K/L (total) 0.870 0.000* 0.817 0.000*
Plasma osteopontin 0.694 0.000*
WOMAC index =Western Ontario and McMaster University. KL =Kellgren and Lawrence grades.
* = signiﬁcantly different at p< 0.05.
Figure 4 Correlation between plasma and synovial ﬂuid osteo-
pontin levels.
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in KL grade 4 were signiﬁcantly elevated compared with those
of KL grade 2 and 3 (p< 0.01), so the synovial ﬂuid level of
OPN correlated with disease severity (Spearman’s r1/4 0.581,
95%CI 0.335, 0.726, p< 0.001).
But Hasegawa et al. [19] found that, in rank correlation
tests, the SF levels of OPN full-length showed no difference
(p= 0.191); however, the levels of OPN N-half and percentage
of N-half correlated with disease severity (p< 0.001). Apart
from one clear outlier in K/L grade 4, showing an extremely
high concentration of OPN N-half (7.8 nM), OPN N-half lev-
els correlated with disease severity (p< 0.001). In addition,
statistically signiﬁcant correlation was found between OPN
N-half and disease severity by K/L grades 1, 2, 3, and 4
(p< 0.001). After adjusting the levels of OPN N-half as well
as % N-half for sex and age, the correlation between % N-half
and the radiographic grading levels remained statistically sig-
niﬁcant (p= 0.015); however, the levels of OPN N-half
showed no difference (p= 0.089).
Recent studies have showed that osteopontin protein depo-
sition and mRNA expression increased with morphological
signs and the severity of matrix degradation in human osteoar-
thritic cartilage [11]. These ﬁndings indicate that osteopontin
expression in osteoarthritic cartilage strongly correlates with
the severity of OA disease. Furthermore, Yagi et al. [22]
showed that the advanced OA cartilage had signiﬁcantlyhigher osteopontin mRNA expression than the minimal OA
cartilage.
Limitation of this study is that, the sample size was not
large enough to make strong conclusions and the effect of joint
sites other than the knee needs to be taken into account. Fur-
ther investigations with standardized assay system in a large
population are warranted to gain insight into the potential util-
ity of OPN in OA patients, especially in synovial ﬂuid.
6. Conclusion
Patients with primary knee OA had higher levels of plasma
osteopontin compared with healthy controls. Osteopontin con-
centrations in plasma and synovial ﬂuid signiﬁcantly corre-
lated with the severity of radiological grade. Further
investigations are needed to elucidate the contribution of oste-
opontin to the pathogenesis of the degenerative process of
osteoarthritis.
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